Thus, while tumor-derived factors can interfere with cDC1 development in PDA (10–14), antigenicity and/or immunotherapy, both of which promote tumor-specific T cells (36, 37), override tumor-dependent cDC1 repression. This evidence concerns the gene MPPE1 and neoplasm.